September 2024

–  HANSIZHUANG (serplulimab) was the first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC –  HETRONIFLY® (serplulimab) is expected to become the first anti-PD-1 monoclonal antibody available in Europe for first-line treatment of ES-SCLC  AHMEDABAD, I

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: